High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
S. Chow, V. Galvis, M. Pillai, R. Leach, E. Keene, A. Spencer-Shaw, A. Shablak, J. Shanks, T. Liptrot, F. Thistlethwaite, R. E. Hawkins
Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 67; DOI: 10.1186/s40425-016-0174-5